Novel bendazac analogues and their salts have been designed and prepared. The resulting compounds (13c-d, 15c, 17c) showed very good aqueous solubility (>100 mg/mL). An in vitro assay showed that most of the resulting compounds had potent protective activity against the oxidative damage. Particularly, compound 13d was also able to enhance the WSP and T-AOC level in the H(2)O(2)/FeCl(3)-induced oxidative damage model, indicating the resulting compound may protect the lens through an antioxidant pathway.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2010.02.061 | DOI Listing |
Eur J Transl Myol
September 2022
Faculty of Science, Engineering and Computing, School of Life Sciences, Pharmacy and Chemistry, Department of Pharmacy, Kingston University, London.
The aim of this study was to identify the efficacy of drug agents for pharmacological Treatment of Presbyopia. Published research papers were reviewed using the relevant terms in PubMed, Science direct, Google scholar, Medline, Google patent, Ovid, Cochrane Database of Systematic Reviews, Scopus. In the initial search, 2270 records were obtained.
View Article and Find Full Text PDFChem Commun (Camb)
March 2022
Department of Pharmacy, Shandong Second Provincial General Hospital, 4 West Duanxing Road, Jinan, Shandong Province 250022, China.
Tumor growth and metastasis are caused by many factors. The complexity means that a multi-target combination therapy strategy should be selected against tumor growth and metastasis. Here, cisplatin (CDDP) and bendazac (Ben) were designed as a novel NSAID-Pt(IV) nanoplatform, which is an effective weapon for combating tumor growth and metastasis.
View Article and Find Full Text PDFJ Pharm Biomed Anal
March 2015
School of Marine Sciences, Ningbo University, Ningbo 315211, Zhejiang, China. Electronic address:
Bioorg Med Chem Lett
April 2010
School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210093, PR China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!